COMMUNIQUÉS West-GlobeNewswire

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

07/11/2024 - 07:00

Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 million Net Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV) 1 sale Operating [...]

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

06/11/2024 - 22:30

Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision [...]

MacroGenics to Participate in Upcoming Investor Conferences

06/11/2024 - 22:30

ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

06/11/2024 - 22:30

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in [...]

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

06/11/2024 - 22:30

DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]

STERIS Announces Financial Results for Fiscal 2025 Second Quarter

06/11/2024 - 22:30

Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7% As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14 Fiscal 2025 outlook [...]

Amedisys Reports Third Quarter 2024 Financial Results

06/11/2024 - 22:30

BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September [...]

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

06/11/2024 - 22:30

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]

DBV Technologies publie ses résultats financiers du troisième trimestre 2024

06/11/2024 - 22:30

Châtillon, France, le 6 novembre (22 :30 CET) 2024 DBV Technologies publie ses résultats financiers du troisième trimestre 2024 DBV clôture le troisième trimestre 2024 avec un solde de trésorerie de 46,4 $ millions [...]

DBV Technologies Reports Third Quarter 2024 Financial Results

06/11/2024 - 22:30

Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN [...]

Surrozen to Present at Upcoming Healthcare Investor Conferences

06/11/2024 - 22:30

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue [...]

BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®

06/11/2024 - 22:35

LOUISVILLE, Ky., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a BrightSpring company and leading independent [...]

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

06/11/2024 - 22:38

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 nov. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]

Monthly information on share capital and company voting rights

06/11/2024 - 22:38

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]

Viemed Healthcare Announces Third Quarter 2024 Financial Results

06/11/2024 - 22:45

LAFAYETTE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced [...]

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

06/11/2024 - 22:45

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp . (Nasdaq: OCX), a diagnostics technology company, announced [...]

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

06/11/2024 - 22:49

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced [...]

Precipio Announces Q3-2024 Shareholder Update Call

06/11/2024 - 23:00

Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2024 [...]

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

06/11/2024 - 23:00

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]